Tag: Samsung Bioepis
Organon, Samsung Bioepis launch HUMIRA biosimilar HADLIMA in US
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible to patients in the United States. This ... Read More
FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11
Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More